When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Rivaroxaban - Wikipedia

   en.wikipedia.org/wiki/Rivaroxaban

   Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [8] It is taken by mouth.

3. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   Medical use. Direct factor Xa inhibitors include rivaroxaban, apixaban and edoxaban, and are types of direct oral anticoagulant (DOAC), which are blood thinning drugs, one of the classes of antithrombotic drugs. [4][5][6] They are commonly prescribed to treat and prevent blood clots in veins, prevent stroke and embolism in people with non ...

4. Which 10 prescription drugs covered under Medicare are ... - AOL

   www.aol.com/10-prescription-drugs-covered-under...

   Janssen Pharms' Xarelto is prescribed to reduce the risk of stroke and blood clots and treat existing blood clots, and reduce the risk for patients with coronary or peripheral artery disease. In ...

5. CHA2DS2–VASc score - Wikipedia

   en.wikipedia.org/wiki/CHA2DS2–VASc_score

   1. Thus, the CHA 2 DS 2 -VASc score is a refinement of CHADS 2[8][10] score and extends the latter by including additional common stroke risk factors, that is, age 65–74, female gender and vascular disease. [11] In the CHA 2 DS 2 -VASc score, 'age 75 and above' also has extra weight, with 2 points. The maximum CHADS 2 score is 6, whilst the ...

6. Ablation stopped AFib in 81% of patients in new study - AOL

   www.aol.com/lifestyle/ablation-stopped-afib-81...

   Using real-world data, researchers found that 81.6% of patients were free from AFib one year after RF-based ablation - a higher percentage than attained in clinical trials.

7. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Rivaroxaban. During the SAR development of rivaroxaban, researchers realized that adding a 5-chlorothiophene-2-carboxamide group to the oxazolidonine core could increase the potency by 200 fold, which had previously been too weak for medical use. In addition to this discovery, a clear preference for the (S)-configuration was confirmed.